Literature DB >> 26609701

Skewed X Inactivation in Women Carrying the FMR1 Premutation and Its Relation with Fragile-X-Associated Tremor/Ataxia Syndrome.

Maria Isabel Alvarez-Mora1, Laia Rodriguez-Revenga, Aina Feliu, Celia Badenas, Irene Madrigal, Montserrat Milà.   

Abstract

BACKGROUND: Fragile-X-associated tremor/ataxia syndrome (FXTAS) is a late-onset multisystem neurological disorder characterized by intention tremor and cerebellar ataxia.
OBJECTIVE: We hypothesized that in FMR1 premutation females with FXTAS, a normal X chromosome might more frequently be inactivated; therefore, the aim of this study was to determine the relationship between skewed X chromosome inactivation (XCI) and FXTAS.
METHODS: We studied the XCI patterns of cases of FMR1 premutation in 10 women with FXTAS and 21 without FXTAS.
RESULTS: The distribution of XCI patterns in the FXTAS and no-FXTAS groups showed differences regarding the allele presenting severe skewed XCI. In the FXTAS group, all cases preferentially inactivated the non-expanded X chromosome, whereas in the no-FXTAS group, all inactivated the expanded X chromosome. Nevertheless, no significant differences were found on comparing XCI frequencies among FMR1 premutation carriers with and without FXTAS. As expected, we found statistically significant differences in the skewed XCI on comparing FMR1 premutation women and controls.
CONCLUSION: Although the reduced sample size and blood XCI patterns are two limitations of this study, our results suggest that the skewed XCI of the normal FMR1 allele may be a risk factor for the development of FXTAS. Furthermore, our findings also support the protective effect of the expression of a normal FMR1 allele.
© 2015 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26609701     DOI: 10.1159/000441566

Source DB:  PubMed          Journal:  Neurodegener Dis        ISSN: 1660-2854            Impact factor:   2.977


  8 in total

1.  Plasma metabolic profile delineates roles for neurodegeneration, pro-inflammatory damage and mitochondrial dysfunction in the FMR1 premutation.

Authors:  Cecilia Giulivi; Eleonora Napoli; Flora Tassone; Julian Halmai; Randi Hagerman
Journal:  Biochem J       Date:  2016-08-23       Impact factor: 3.857

Review 2.  Update on the Clinical, Radiographic, and Neurobehavioral Manifestations in FXTAS and FMR1 Premutation Carriers.

Authors:  Deborah A Hall; Erin Robertson; Annie L Shelton; Molly C Losh; Montserrat Mila; Esther Granell Moreno; Beatriz Gomez-Anson; Verónica Martínez-Cerdeño; Jim Grigsby; Reymundo Lozano; Randi Hagerman; Lorena Santa Maria; Elizabeth Berry-Kravis; Joan A O'Keefe
Journal:  Cerebellum       Date:  2016-10       Impact factor: 3.847

3.  Placebo Response in Fragile X-associated Tremor/Ataxia Syndrome.

Authors:  Emily J Hill; Christopher G Goetz; Glenn T Stebbins; Randi Hagerman; Bichun Ouyang; Deborah A Hall
Journal:  Mov Disord Clin Pract       Date:  2020-03-04

4.  Heterozygous CDKL5 Knockout Female Mice Are a Valuable Animal Model for CDKL5 Disorder.

Authors:  Claudia Fuchs; Laura Gennaccaro; Stefania Trazzi; Stefano Bastianini; Simone Bettini; Viviana Lo Martire; Elisa Ren; Giorgio Medici; Giovanna Zoccoli; Roberto Rimondini; Elisabetta Ciani
Journal:  Neural Plast       Date:  2018-05-27       Impact factor: 3.599

5.  FMR1 expression in human granulosa cells increases with exon 1 CGG repeat length depending on ovarian reserve.

Authors:  Julia Rehnitz; Diego D Alcoba; Ilma S Brum; Jens E Dietrich; Berthe Youness; Katrin Hinderhofer; Birgitta Messmer; Alexander Freis; Thomas Strowitzki; Ariane Germeyer
Journal:  Reprod Biol Endocrinol       Date:  2018-07-07       Impact factor: 5.211

Review 6.  Fragile X-Associated Tremor/Ataxia Syndrome (FXTAS): Pathophysiology and Clinical Implications.

Authors:  Ana Maria Cabal-Herrera; Nattaporn Tassanakijpanich; Maria Jimena Salcedo-Arellano; Randi J Hagerman
Journal:  Int J Mol Sci       Date:  2020-06-20       Impact factor: 5.923

Review 7.  Molecular Correlates and Recent Advancements in the Diagnosis and Screening of FMR1-Related Disorders.

Authors:  Indhu-Shree Rajan-Babu; Samuel S Chong
Journal:  Genes (Basel)       Date:  2016-10-14       Impact factor: 4.096

8.  Evidence for Three Subgroups of Female FMR1 Premutation Carriers Defined by Distinct Neuropsychiatric Features: A Pilot Study.

Authors:  Lauren M Schmitt; Kelli C Dominick; Rui Liu; Ernest V Pedapati; Lauren E Ethridge; Elizabeth Smith; John A Sweeney; Craig A Erickson
Journal:  Front Integr Neurosci       Date:  2022-01-03
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.